

Research

Corresponding author**Felice Strollo, MD, Prof.**

Endocrinology and Metabolism

Elle-di, Via degli Scipioni 175

00192, Rome, Italy

Tel. +39.06.3219639

E-mail: felix.strollo@gmail.com

Volume 2 : Issue 1

Article Ref. #: 1000DROJ2126

Article History**Received:** July 27th, 2016**Accepted:** August 10th, 2016**Published:** August 10th, 2016**Citation**

Strollo F, Guarino G, Armentano V, et al on behalf of AMD-OSDI Italian Study Group on Injection Techniques. Unexplained hypoglycaemia and large glycaemic variability: Skin lipohypertrophy as a predictive sign. *Diabetes Res Open J.* 2016; 2(1): 24-32. doi: [10.17140/DROJ-2-126](https://doi.org/10.17140/DROJ-2-126)

Unexplained Hypoglycaemia and Large Glycaemic Variability: Skin Lipohypertrophy as a Predictive Sign

Felice Strollo, MD, Prof.¹; Giuseppina Guarino, MD²; Vincenzo Armentano, MD³; Gennaro Clemente, MD⁴; Emilia Martedi, MD⁵; Stefano de Riu, MD⁶; Iole Gaeta, MD³; Gerardo Corigliano, MD⁷; Antonio Ceriello, MD, Prof.⁸; Sandro Gentile, MD, Prof.² on behalf of AMD-OSDI Italian Study Group on Injection Techniques

¹Endocrinology and Metabolism, Elle-di, Rome, Italy²Department of Internal Medicine, Second University of Naples, Naples, Italy³Diabetes Unit, ASL Napoli 1, Naples, Italy⁴Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Naples, Italy⁵Diabetes Unit AID Portici, Naples, Italy⁶Diabetes and Metabolism Unit, ASL Salerno 1, Salerno, Italy⁷Diabetes and Metabolism AID Via Mariano D'Ayala 1, Naples, Italy⁸Department of Cardiovascular and Metabolic Diseases at IRCCS MultiMedica in Milan, Italy**ABSTRACT**

Rationale and Aims of the Study: Strong efforts to keep DM under control cause frequent hypoglycaemic events (Hypos) with relevant clinical, social and economic consequences. Moreover, long-lasting rebound hyperglycaemia and patients' poor compliance or exaggerated corrective behaviors cause high glucose variability (GV). Several Hypos are unexplained and might be due to inappropriate insulin administration. In fact, the reported association between lipohypertrophy (LH) and Hypos might depend on poor education. The purpose of this study was to assess whether LH rate might predict Hypos and GV in insulin treated patients.

Methods: This was an observational, retrospective, multicentre study involving 387 DM patients referred to specialized settings for Hypos and/or GV carefully performing self monitoring blood glucose (SMBG) and filling in a structured Hypo questionnaire.

Results: Twenty-eight percentages had at least one severe and 72% one non-severe episode (average: 3.3 Hypos/week). T1DM, long standing disease and high insulin doses were significantly associated with LH and impressive odds ratio (ORs) were reached by unexplained Hypos/GV (UHGV; $p < 0.001$). The presence of LH predicted about 77.1% of UHGV, which displayed a 4.38 times higher risk when LH was combined with low socio-economic level, loneliness, poor metabolic control, disease complications and inappropriate injection technique (longer/larger and/or reused needles, missed injection site rotation). In multivariate analysis, the latter was still strongly associated with UHGV.

Conclusions: In the presence of UHGV, injection sites should be systematically explored in search of LH areas. Furthermore, appropriate educational activities should be implemented to improve patients' behavior, including periodical verification of their injection habits.

ACKNOWLEDGEMENTS

*AMD is the Italian acronym for the Association of Diabetes Specialists and OSDI is the Italian acronym for Diabetes Care Health Professionals.

**Members of the Study Group. Coordinator: Gentile S. Collaborators: Botta A, Cucco L, De Rosa N, De Riu S, Garrapa G, Gentile L, Grassi G, Lalli C, Lo Grasso G, Marcone TM, Speese K, Sudano M, Tatti P, Tonutti L, Chiandetti R.

Copyright

©2016 Strollo F. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

KEYWORDS: Unexplained hypoglycaemia; Hypoglycaemia; Glucose variability; Lipohypertrophy; Diabetes.

ABBREVIATIONS: AMD: Associazione Medici Diabetologi (Association of Clinical Diabetologists); BG: Blood Glucose; SH: Severe Hypoglycaemia; NSH: Symptomatic non-severe hypoglycaemia; Hypos: Hypoglycaemic events; GV: Glycaemic Variability; LH: Lipohypertrophy; T1DM: Type 1 Diabetes Mellitus; SMBG: Self Monitoring Blood Glucose; UHGV: Unexplained Hypos/Glycaemic Variability.

INTRODUCTION

The main goal of diabetes treatment is to maintain an adequate metabolic control in order to prevent or delay disease complications.¹ However, when too strong efforts are made to keep glycated haemoglobin (HbA1c) within target levels, patients often are at a high risk for hypoglycaemia.² Hypoglycaemic episodes (Hypos), especially severe ones, have a relevant clinical, social and economic impact. From a clinical standpoint, they are characterized by several symptoms ranging from general discomfort to seizures and coma eventually resulting into either sudden cardiac arrhythmic death or lethal brain damage due to long-lasting cerebral tissue glucose deprivation.³ Repeated severe Hypos are associated with a higher cardiovascular risk,⁴ and dementia.^{5,6} Even mild symptomatic hypoglycaemia is associated with an increased risk of cardiovascular events and all-cause hospitalization/mortality.⁷

Hypoglycaemia is also a key driver for direct and indirect costs. In greater detail, up to one third of people with long standing type 1 diabetes mellitus (T1DM) and one fifth of insulin treated people with type 2 diabetes mellitus (T2DM) suffer from one or more severe Hypos every year.^{8,9} This generates a high economic burden in terms of both direct (>3000 € each hospital admission all over Europe) and indirect costs (mostly due to patients or their relatives abstaining from work).^{10,11}

Moreover, from a social point of view, several studies suggest that Hypos may disrupt quality of life (QoL) in terms of driving efficiency, work performance and recreational pursuits¹² and thereby negatively affect patient's mood and health perception.^{13,14} In addition, Hypos are by far the strongest factors hindering metabolic control in insulin-treated patients^{15,16} as long-lasting hyperglycaemia invariably follows Hypos due both to rebound counter-regulatory hormone reaction and to previous frightening experiences causing excessive corrective behaviour and poor adherence to therapy. As a consequence of that high glucose variability (GV) is also often observed.^{17,18} Iatrogenic causes explain nearly all Hypos in people with T1DM.^{19,20} Predictable triggers (i.e. skipped meals, strenuous exercise, insulin overdose, neoplasms and chronic renal or liver disease), as well as, defective glucose counter-regulation and established hypoglycaemia-associated autonomic failure have been extensively described.²¹⁻²³

On the other hand, many Hypos are difficult to explain on the basis of the above listed factors and might also depend on improper insulin administration. This includes either accidental intramuscular injection through excessively long needles or bad patients' habits, like shooting insulin into skin nodules.²⁴⁻²⁶ Diabetologists spend too little time in educating patients to perform correct insulin injections²⁷ and, as a consequence of that, several groups have been describing a close relationship between recurrent hypoglycaemia and lipohypertrophy (LH) so far.²⁷⁻³⁰ In fact, patients and clinicians are not used to systematically and thoroughly investigate upon any possible reasons behind unexplained Hypos.

The main purpose of this study was to assess whether LH occurrence (Figure 1) might predict a high Hypos or GV rate in insulin treated patients and, if so, whether high Hypo rates might depend on inappropriate injection habits like performing insulin shots into LH nodules with long needles.



Figure 1: The red arrow points to a prominent LH nodule on the left thigh of a woman with T1DM.

PATIENTS AND METHODS

This was an observational, retrospective, multicentre study on T1 or T2DM patients referring to five diabetes outpatient centres.

Eligibility criteria were: age ≥ 18 years, insulin treatment (>2 daily shots) for at least the last 12 months, as well as, frequent unexplained Hypos and/or unjustified GV over the last three months.

Exclusion criteria: Hospitalization, use of insulin syringes, oral hypoglycaemic agents or steroids, neoplastic, liver or kidney diseases, pregnancy.

The study was approved by the Ethics Committee of the five participating centres and all patients agreed to participate by signing their informed consent to the study. The latter was performed according to the Helsinki Declaration.

All enrolled patients filled in the HYPOS-1 questionnaire to collect information on Hypos or GV as previously described.^{31,32} Briefly, the questionnaire investigated upon socio-demographic and clinical characteristics including age, gender, education level, employment, living status, spouse/caregiver support, number of daily medications (other than blood glucose lowering agents), number of severe hypoglycaemic episodes during the past 12 months, and number of symptomatic Hypos in the past 4 weeks. The above mentioned time intervals were chosen according to the ability of insulin treated subjects to recall such episodes as ascertained in previous studies.²³ Study investigators completed a web-based electronic clinical record form (eCRF) where patients were identified by a unique ID number, which was also used as a key linkage to merge their data with questionnaire answers and to anonymously analyse them thereafter.

The evaluation-validation of Hypos and GV was based on the analysis of patients' self-monitored blood glucose (SMBG) recordings using a twice-a-day "staggered" scheme as depicted in Figure 2. This pattern is characterized by high flexibility, which makes it better tolerated and accepted with consequent greater patient adherence to given instructions, and is strongly supported by specialists, as well, because of its easier and immediate interpretation.²⁴ Patients were also trained to perform additional glucose checks in case of sudden hypoglycaemic symptoms.

In greater detail:

1. Hypo was defined as the occurrence of one or more symptoms of hypoglycaemia (such as palpitations, tiredness, sweating, hunger, dizziness and tremor) and a confirmed blood glucose (BG) meter reading of ≤ 70 mg/dL, according to ADA statements.¹⁵ Frequent unexplained hypoglycaemia was defined as having a Hypo atleast once a week in the absence of any identified precipitating event, such as changes in insulin dosage, diet composition or amount of physical activity. Hypos were further defined as severe (SH; BG<50 mg/dl), and non-severe (NSH; $50^{th} > BG < 70$ mg/dl).³³⁻³⁵

2. GV was investigated by a validated questionnaire already

used in previous studies.^{28,31,36} As GV has no universally accepted definition, patients were defined as having GV if blood glucose values unpredictably and inexplicably swung from < 60 mg/dL to > 250 mg/dL on a continuous basis at least three times a week.^{28,31,36}

3. LH was looked for at all insulin injection sites using a previously described validated methodology: when filling in their questionnaires patients also indicated all sites they used³⁵ and the medical staff checked them for the presence of skin lesions according to a structured protocol, as previously described.^{37,38}

Participating centres screened 3710 consecutive ≥ 18 year old outpatients treated with insulin pens for at least two years and free from any kind of (i) steroid-based treatment regimens, (ii) chronic kidney/liver disease or (iii) cancer. Two thousand three hundred out of them (62%) had experienced at least one episode of either SH or NSH over the last three months. After excluding all cases associated with factors known to cause hypoglycaemia, including dietary errors, inadequate insulin dosage, poor treatment adherence, occasional utilization of drugs endowed with intrinsic hypoglycaemic effects, acute gastrointestinal troubles, only 387 subjects (16.8%) with unexplained GV and/or Hypos were finally included in the study: 294 had both Hypos and GV, 23 only Hypos and 70 only GV. In line with the typical distribution among people with diabetes attending such centre, 80 out of the 387 enrolled subjects had T1DM. Main clinical participant characteristics are described in Table 1, whereas needle length and gauge are summarized in Table 2. Participants using premixed or NPH insulin (9.3% and 2.8%, respectively) or 12 mm length and 29 gauge needles (1.8% each) turned out to be only a minority and were therefore excluded from subsequent statistical evaluation to avoid any bias due to treatment in homogeneity. No patient used any 33 gauge needles.

Statistical Analysis

Continuous variables were reported as means \pm standard deviation (SDs) and were compared between groups by student's *t*-test for independent samples or analysis of variance (ANOVA) as needed. Non-parametric Mann-Whitney *U*-test was used when

'Staggered' SMBG regimen

	Pre-Breakfast	Post-Breakfast	Pre-Lunch	Post-Lunch	Pre-Dinner	Post-Dinner	Bedtime
Monday	X	X					
Tuesday			X	X			
Wednesday					X	X	
Thursday	X	X					
Friday			X	X			
Saturday					X		
Sunday	X	X				X	

Figure 2: Self-monitoring blood glucose tabs weekly grid, according to the IDF 2015 scheme.

Subjects enrolled	n=387
Male gender (%)	45.5
Age (years) (range)	61±16 41-77
BMI (Kg/m ²)	29±8
Type 1 diabetes n.(%)	81 (20.9%)
HbA1c (%)	8.4±1.2
DM duration (years) (range)	13±9 5-23
Injections/day (n.)	3.8±1.2
Insulin treatment (years)	10±9
Insulin dosage (IU/day)	44±25
Basal insulin analogues n.(%)	340 (87.9%)
Short-acting insulin analogues n.(%)	360 (93.0%)
Premixed Insulin n.(%)	36 (93%)
Insulin-NPH n.(%)	11 (2.8%)

Table 1: Characteristics of insulin pen using patients.

length (mm)	Subjects n. (%)	Gauge (G)	Subjects n. (%)
4	58 (14.9)	33	-
5	61 (15.8)	32	58 (14.5)
6	115 (29.7)	31	176 (45.5)
8	146 (37.7)	30	146 (37.7)
12	7 (1.8)	29	7 (1.8)

Table 2: Needle length and gauge.

appropriate. Categorical variables were summarized as rate or percentage and their bivariate associations were evaluated by Chi-square or Fisher exact tests. Based on the fact that a significant association had been already documented in the Hypos-1 study^{33,34} among the presence of SH/NSH and diabetes complications, type of insulin preparation or treatment with drugs associated with reduced Hypo awareness including angiotensin-converting-enzyme inhibitor (ACE inhibitor) or beta-blockers,³⁹⁻⁴¹ we also evaluated the relationship between LH lesions and these factors based on univariate followed by Poisson multivariate model analysis. Patients were grouped and compared according to their LH identification rate characteristics, namely by considering those identified by all health providers (HPs) vs. those identified by none of them. Odds ratios (ORs) for LH were reported along with their 95% confidence intervals (CI). In addition, the relationship between needle length/gauge and the presence of LH was also evaluated according to the same statistical procedure by taking into account school education, employment and marital status or living conditions. The analysis were carried out using STATA software, version 12 (Stata Corp, College Station, TX, USA) and *p*-values <0.05 were accepted *a priori* as statistically significant.

RESULTS

General patient characteristics are described in Table 1. Twenty-eight percentages subjects had faced at least one SH, and 72% one NSH in the last four weeks, with an average of 3.3 episodes

per week. Table 2 describes needle utilization rate as referred to length and gauge and shows that lengths >4-5 mm and gauges <32 were largely preferred. Table 3 clearly describes the relationship between unexplained GV/Hypos and LH (*p*<0.0001), characterized by a significantly high OR (7.18) for GV/Hypos in case of LH.

Tables 4 and 5 describe the results of univariate analysis by comparing subjects with LH to those without LH regardless of general/demographic parameters, insulin treatment features, injection site rotation habits, as well as, needle reuse rate, utilization of drugs associated with reduced hypoglycaemia awareness, employment, school education, living conditions and marital status. In greater detail, 40% patients used the same needle at least twice and 44.2% at least three times; only 15.8% subjects changed needles at each injection. Tables clearly show that needle reuse and failure to rotate injection sites associated to a high LH risk.

T1DM, long standing disease and high insulin requirements significantly associated to LH, and very high ORs were attained by unexplained Hypos (4.43), GV (5.23) or both (7.18). The risk of diabetes complications was significantly higher in subjects with LH (retinopathy 4.12; nephropathy 4.19; lower limb complications 4.48; sensory-motor neuropathy 5.18, and autonomic neuropathy 3.72) (Figures 3 and 4). Any use of drugs associated with reduced hypoglycaemia awareness turned out to be irrelevant.

		GV/Hypos		
		yes	no	total
LH	yes	287 (74.2%)	11 (2.8%)	298
	no	7 (1.8%)	82 (21.2%)	89
	total	294	94	387

Table 3: Association between unexplained glycaemic variability (GV)/Hypoglycaemic episodes (Hypos) and lipohypertrophy (LH); n and (%) are displayed within cells (χ^2 test, $p < 0.0001$).

	Lipohypertrophy				
	Overall n=387	No n=89 (22.9%)	Yes n=298 (77.1%)	OR (95% CI)	p
Male gender	187 (48.4%)	87 (46.8%)	100 (50.1%)	1.20 (0.88-1.64)	0.243
Age (years)	61±16	63±12	61±10	0.90 (0.81-1.00)	0.051
BMI (Kg/m ²)	29±6	29±6	29±6	0.99 (0.96-1.02)	0.492
Type 1 diabetes	81 (20.9%)	20 (25.2%)	61 (75.3%)	2.64 (2.14-2.74)	<0.001
HbA1c (%)	7.8±1.3	7.5±1.1	8.3±1.2	1.30 (1.14-1.48)	<0.001
DM duration (years)	17±10	17±9	20±8	1.28 (1.10-1.49)	<0.001
Injections/day n.	3.8±2.8	3.7±3.5	3.7±.9	1.00 (0.94-1.06)	0.991
Insulin treatment (years)	8±9	7±9	12±6	1.46 (1.23-1.74)	<0.001
Insulin dosage (IU/day)	44±25	41±19	49±18	1.13 (1.06-1.21)	<0.001
Basal insulin analogues n. (%)	340 (87.9%)	238 (70.0%)	102 (30.0%)	3.13 (1.80-5.47)	<0.001
Short-acting insulin analogues n. (%)	360 (93.0%)	298 (82.8%)	62 (17.2%)	3.27 (2.68-3.78)	<0.001
Glycaemic variability n. (%)	364 (94.1)	109 (29.9)	255 (70.1)	4.43 (3.11-6.33)	<0.0001
Hypoglycaemia n. (%)	317 (81.9)	27 (8.5)	290 (91.5)	5.23 (3.54-7.74)	<0.0001
Needle reuse n. (%)	326 (84.2)	61 (18.7)	326 (81.3)	4.27 (3.89-4.81)	<0.001
No injection site rotation n. (%)	349 (90.2)	38 (10.9)	349 (89.1)	5.11 (4.76-5.56)	<0.001
Drugs associated with reduced awareness (%)					
ACE-Inhibitors	30	48	52	1.29 (0.82-1.74)	0.219
Beta-blockers	25	47	51	0.98 (0.79-1.24)	0.317

Table 4: Univariate analysis of clinical parameters with respect to lipohypertrophy in insulin pen using patients. From 387 subjects with hypoglycaemia and/or glycaemic variability, 23 were Hypos- and 70 were GV-. Because of the low number of subjects using premix or NPH insulin, these were not included in the statistical evaluation

	Lipohypertrophy				
	Overall n=387	No n=89 (22.9%)	Yes n=298 (77.1%)	OR (95% CI)	p
needle length n. (%)					
4 mm	58 (14.9%)	47 (81.1)	11 (18.9)	2.18 (2.02-2.56)	<0.01
5 mm	61 (15.8%)	50 (82.0)	11 (18.0)	2.27 (1.79-2.84)	<0.01
6 mm	115 (29.7%)	44 (38.3)	71 (61.7)	1.94 (1.11-2.73)	<0.01
8 mm	146 (37.7%)	31 (21.2)	115 (78.8)	2.22 (2.08-3.29)	<0.01
12 mm	7 (1.8%)	0 (0.0)	7 (100.0)	-	-
needle gauge n. (%)					
32	58 (14.5)	47 (81.1)	11 (18.9)	2.15 (1.95-2.48)	<0.01
31	176 (45.5)	85 (48.3)	91 (51.7)	1.22 (0.89-1.67)	0.257
30	146 (37.7)	37 (25.3)	109 (74.7)	1.56 (1.20-1.78)	<0.01
29	7 (1.8)	0 (0.0)	7 (100.0)	-	-
needle reuse n. (%)	326 (84.2)	61 (18.7)	326 (81.3)	4.27 (3.89-4.81)	<0.001
no injection site rotation n. (%)	349 (90.2)	38 (10.9)	349 (89.1)	5.11 (4.76-5.56)	<0.001

Table 5: Univariate analysis of needle length and gauge with respect to lipohypertrophy in insulin pen using patients.




Figure 3: Frequency of LH and diabetes complications. All differences were statistically significant ($p < 0.001$). CV: Cardio-CerebroVascular complications; R: Retinopathy, Neph: Nephropathy; PA: Peripheral Artery disease; Per Neuro: Peripheral Neuropathy; Aut Neuro: Autonomic Neuropathy.




Figure 4: Complication rates in subjects with (dark green bars) or without (light green bars) hypoglycaemia/glycaemic variability; 57% had more than one complication and 32% more than two complications. All the differences were statistically significant ($p < 0.001$) except for PA. CV: Cardio-CerebroVascular complications; R: Retinopathy; Neph: Nephropathy; PA: Peripheral Artery disease; Per Neuro: Peripheral Neuropathy; Aut Neuro: Autonomic Neuropathy.

With reference to the socio-economic status, the level of education did not affect the association between Hypos and LH. The same applied to living conditions: in fact no significant association was found between Hypos and LH in those who lived alone, or were unmarried/separated/divorced.

Finally, as shown in Figures 5 and 6, the risk of developing LH was associated with needle characteristics: both longer and larger needles were related to a higher LH risk ($p < 0.001$). Needle reuse and missed injection site rotation were also LH risk factors strongly associated with unexplained Hypos /GV.

After multivariate analysis (Table 6) short-acting and basal insulin analogues kept highly associated with increased LH risk in T1DM patients with unjustified Hypos /GV.

When pooling socio-economic and family statuses under the term of living conditions and putting together all diabetes

complications, we could also confirm both complex parameters to be strongly associated to LH and GV/Hypos. Likewise, needle length/gauge, needle reuse and missed injection site rotation kept their significant role as risk factors for LH in the presence of unexplained GV/Hypos. This was not the case, instead, with either disease duration or daily insulin dosage.

DISCUSSION

Hypoglycaemia is an acute complication increasing diabetes morbidity and mortality. It is also responsible for a heavy—still not fully defined—economic burden. However it is by far the strongest limiting factor in terms of tight glycaemic control in insulin-treated patients.^{17,18} In people with T1DM predictable triggers explain many hypoglycaemic events (T1DM),^{19,20} including skipped meals, strenuous exercise, high insulin doses, chronic renal or liver disease, as well as defective glucose counter-regulation and established hypoglycaemia-associated auto-




Figure 5: Relationship between needle length and lipohypertrophy. * $p < 0.001$




Figure 6: Relationship between needle gauge and lipohypertrophy. * $p < 0.001$.

	OR (95% CI)	p
Age (years)	0.91 (0.76-1.10)	0.338
Type 1 diabetes n. (%)	0.84 (0.39-1.80)	0.656
HbA1c (%)	2.00 (1.85-2.19)	<0.001
DM duration (years)	1.07 (0.80-1.44)	0.627
Insulin dose (IU/day)	2.88 (2.56-2.99)	<0.001
Hypos/GV	4.85 (4.02-5.30)	<0.0001
Diabetes complications	2.99 (2.34-3.51)	<0.001
Living status	3.15 (2.89-3.58)	<0.001
Marital status	3.22 (2.97-3.69)	<0.001
Pen needle length (mm)	2.98 (2.56-2.25)	<0.001
Gauge (G)	3.56 (2.60-3.78)	<0.001
Needle reuse	3.78 (3.06-4.12)	<0.01
Failure to rotate injection sites	4.22 (3.78-4.86)	<0.01

Table 6: Multivariate analysis of subjects' characteristics potentially associated to lipohypertrophy.

nomic failure.²¹⁻²³

Nevertheless, apparently inexplicable hypoglycaemic episodes may be related to incorrect insulin injection techniques including the use of long needles—eventually allowing insulin injection into the subcutaneous muscle tissue—or patients' incorrect habit to inject insulin into LH nodules.²⁵⁻²⁷

In the series of patients in the Hypos-1 study^{32,33} a high rate of SHs, NSHs and GV was reported (28%, 70% and 56%, respectively). Accordingly, our data documented an overall 62% Hypos rate, 16.8% in fact being inexplicable and showing a strong correlation with the presence of LH, as well as, with all known associated factors.

The profile of people with diabetes displaying inexplicable Hypos/GV included the presence of LH nodules, as well as, poor metabolic control, high micro-/macrovascular complication rates, longer/larger needles, missed injection site rotation, low socio-economic level and solitary life. The risk for LH to be deemed as responsible for unexplained Hypos or GV rose to 4.38 in the case of simultaneously occurring above mentioned factors and LH.

Conversely, the presence of LH was able to predict about 77.1% of unexplained Hypos/GV. Indeed, factors known to be associated with LH were also present at a high rate in subjects with such phenomena.

However, the remaining 22.9% people without any LH nodules experienced unexplained Hypo/GV too. It might depend on the fact that identifying subtle skin lesions is very difficult so that “no identified LH” is not equivalent at all to “absence of any LH”. In fact, we feel like stressing what was already pointed out by other authors^{28,31,36}: education on injection techniques is still inadequate and diabetes specialists and dedicated nurses should make their best to prevent patients from causing themselves any

skin damage through wrong habits.

Our conclusion then is that, in the presence of unexplained Hypos/GV, injection sites should be systematically and thoroughly explored in search of LH areas. Furthermore, appropriate educational activities should be implemented to improve patients' behaviour, including periodical investigation on their injection habits.

A recent meta-analysis of population based studies⁴² including 46 publications (n=532, 542) found Hypos to occur quite frequently among people on insulin: mild/moderate events were in fact about 50% with an incidence of 23 episodes per person-year while severe episodes were about 21% with an incidence of 1 event per person-year.

Should we ideally select people with unexplained Hypos from the extremely large number of patients mentioned above, we would deal with an impressive cohort: in that case the systematic utilization of a suitable LH identification protocol followed by patient rehabilitation would be expected to dramatically reduce Hypo prevalence, incidence and health consequences, as well as, the costs related to this frightening, yet neglected, complication of insulin treatment.

Further studies are warranted to assess whether educational activities like those reported in our study may result into a decreased burden of diabetes as for unexplained hypoglycaemia.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabe-

- tes. *N Engl J Med.* 2008; 359: 1577-1589. doi: [10.1056/NEJMoa0806470](https://doi.org/10.1056/NEJMoa0806470)
2. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008; 358: 2545-2559. doi: [10.1056/NEJMoa0802743](https://doi.org/10.1056/NEJMoa0802743)
3. Cryer PE. The barrier of hypoglycemia in diabetes. *Diabetes.* 2008; 57: 3169-3176. doi: [10.2337/db08-1084](https://doi.org/10.2337/db08-1084)
4. Goto A, Arah OA, Goto M, Ierauchi Y, Noda M. Severe hypoglycemia and cardiovascular disease: Systematic review and meta-analysis with bias analysis. *BMJ.* 2013; 347: f4533. doi: [10.1136/bmj.f4533](https://doi.org/10.1136/bmj.f4533)
5. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. *JAMA.* 2009; 301: 1565-1572. doi: [10.1001/jama.2009.460](https://doi.org/10.1001/jama.2009.460)
6. Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. *JAMA Intern Med.* 2013; 173: 1300-1306. doi: [10.1001/jamainternmed.2013.6176](https://doi.org/10.1001/jamainternmed.2013.6176)
7. Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: A nationwide population-based study. *Diabetes Care.* 2013; 36: 894-900. doi: [10.2337/dc12-0916](https://doi.org/10.2337/dc12-0916)
8. Leiter LA, Yale J-F, Chiasson J-L, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. *Can J Diabetes.* 2005; 29: 186-192.
9. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. *Diabet Med.* 2008; 25: 245-254. doi: [10.1111/j.1464-5491.2007.02341.x](https://doi.org/10.1111/j.1464-5491.2007.02341.x)
10. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. *Diabetes Care.* 2003; 26: 1176-1180. doi: [10.2337/diacare.26.4.1176](https://doi.org/10.2337/diacare.26.4.1176)
11. Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: Results from a European online survey. *Expert Rev Pharmacoecon Outcomes Res.* 2013; 13: 123-130. doi: [10.1586/erp.12.80](https://doi.org/10.1586/erp.12.80)
12. Graveling AJ, Frier BM. Hypoglycaemia: An overview. *Prim Care Diabetes.* 2009; 3: 131-139. doi: [10.1016/j.pcd.2009.08.007](https://doi.org/10.1016/j.pcd.2009.08.007)
13. Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: A narrative review. *Diabet Med.* 2012; 29: 293-302. doi: [10.1111/j.1464-5491.2011.03416.x](https://doi.org/10.1111/j.1464-5491.2011.03416.x)
14. Nicolucci A, Cucinotta D, Squatrito S, et al. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. *Nutr Metab Cardiovasc Dis.* 2009; 19(1): 45-53. doi: [10.1016/j.numecd.2007.12.005](https://doi.org/10.1016/j.numecd.2007.12.005)
15. Cryer PE. The barrier of hypoglycemia in diabetes. *Diabetes.* 2008; 57: 3169-3176.
16. Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: Physiology, pathophysiology, and management. *Clin Diabetes.* 2006; 24: 115-121. doi: [10.2337/diaclin.24.3.115](https://doi.org/10.2337/diaclin.24.3.115)
17. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia. *Diabetes Care.* 2005; 28: 1245-1249. doi: [10.2337/diacare.28.5.1245](https://doi.org/10.2337/diacare.28.5.1245)
18. Barnett AH, Craddock S, Fisher M, Hall G, Hughes E, Middleton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. *Int J Clin Pract.* 2010; 64: 1121-1129. doi: [10.1111/j.1742-1241.2009.02332.x](https://doi.org/10.1111/j.1742-1241.2009.02332.x)
19. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. *Am J Med.* 1991; 90: 450-459. doi: [10.1016/0002-9343\(91\)80085-Z](https://doi.org/10.1016/0002-9343(91)80085-Z)
20. The DCCT Research Group. Hypoglycemia in the diabetes control and complications trial. *Diabetes.* 1997; 46: 271-286. doi: [10.2337/diab.46.2.271](https://doi.org/10.2337/diab.46.2.271)
21. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycemia in type 1 and insulin-treated type 2 diabetes: A population based study. *Diabet Med.* 2005; 22: 749-755. doi: [10.1111/j.1464-5491.2005.01501.x](https://doi.org/10.1111/j.1464-5491.2005.01501.x)
22. Heller SR, Choudhary P, Davies C, et al. Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. *Diabetologia.* 2007; 50: 1140-1147. doi: [10.1007/s00125-007-0599-y](https://doi.org/10.1007/s00125-007-0599-y)
23. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. *Diabetes Metab Res Rev.* 2003; 19: 232-240. doi: [10.1002/dmrr.377](https://doi.org/10.1002/dmrr.377)
24. International Diabetes Federation. Clinical guidelines task force. Global guideline for type 2 diabetes. 2012. Web site. <http://www.idf.org/guideline-type-2-diabetes>. Accessed July 26, 2016

25. Gentile S, Agrusta M, Guarino G, et al. Metabolic consequence of incorrect insulin administration techniques in aging subjects with diabetes. *Acta Diabetol.* 2011; 48: 121-125. doi: [10.1007/s00592-009-0172-x](https://doi.org/10.1007/s00592-009-0172-x)
26. Young RJ, Hannan WJ, Frier BM, Steel JM, Duncan JPL. Diabetic lipohypertrophy delays insulin absorption. *Diabetes Care.* 1984; 7: 479-480. doi: [10.2337/diacare.7.5.479](https://doi.org/10.2337/diacare.7.5.479)
27. Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. *Diabetes Res Clin Pract.* 2007; 77: 231-236. doi: [10.1016/j.diabres.2006.12.023](https://doi.org/10.1016/j.diabres.2006.12.023)
28. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. *Diabetes Metab.* 2013; 39: 445-453. doi: [10.1016/j.diabet.2013.05.006](https://doi.org/10.1016/j.diabet.2013.05.006)
29. Rosak C, Burkard G, Hoffmann JA, Humburg E, Look D, Landgraf R. Metabolic effect and acceptance of an insulin pen treatment in 20,262 diabetic patients. *Diab Nutr Metab.* 1993; 6: 139-145. Web site. <http://cat.inist.fr/?aModele=afficheN&cpsidt=4911401>. Accessed 2016
30. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. *Br Med J.* 2003; 327: 383-384. doi: [10.1136/bmj.327.7411.383](https://doi.org/10.1136/bmj.327.7411.383)
31. Strauss K, De Gols, Hannel I, Partanen T-M, Frid A. A pan-european epidemiologic study of insulin injection technique in patients with diabetes. *Pract Diab Int.* 2002; 19: 71-76. doi: [10.1002/pdi.314](https://doi.org/10.1002/pdi.314)
32. Giorda CB, Ozzello A, Gentile S, et al. HYPOS-1 Study Group of AMD. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. *Acta Diabetol.* 2015; 52: 845-853. doi: [10.1007/s00592-015-0713-4](https://doi.org/10.1007/s00592-015-0713-4)
33. Giorda CB, Ozzello A, Gentile S, et al. Incidence and correlates of hypoglycemia in type 2 diabetes. The Hypos-1 study. *J Diabetes Metab.* 2014; 5: 3.
34. American Diabetes Association. Clinical practice recommendations 2008. Hypoglycaemia and employment/licensure. *Diabetes Care.* 2008; 31(Suppl 1): S94.
35. American Diabetes Association. Standards of medical care in diabetes-2012. *Diabetes Care.* 2012; 35(Suppl 1): S11-S63. doi: [10.2337/dc12-s011](https://doi.org/10.2337/dc12-s011)
36. de Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008-2009 insulin injection technique questionnaire survey. *J Diabetes.* 2010; 2: 168-179. doi: [10.1111/j.1753-0407.2010.00077.x](https://doi.org/10.1111/j.1753-0407.2010.00077.x)
37. Gentile S, Guarino G, Giancaterini A, Guida P, Stollo F, AMD-OSDI Italian Injection Technique Study Group. A suitable palpation technique to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. *Springe Plus.* 2016; 5: 563. doi: [10.1186/s40064-016-1978-y](https://doi.org/10.1186/s40064-016-1978-y)
38. Gentile S, Stollo F, Guarino G, et al on behalf of the AMD-OSDI* Italian Study Group. Factors hindering correct identification of unapparent lipohypertrophy. *J Diabetes Metab Disord Control.* 2016; 3(2): 00065. Web site. <http://medcraveonline.com/JDMDC/JDMDC-03-00065.pdf>. Accessed July 26, 2016
39. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. *Lancet.* 2001; 357: 1248-1253. doi: [10.1016/S0140-6736\(00\)04405-6](https://doi.org/10.1016/S0140-6736(00)04405-6)
40. Mills GA, Horn JR. Beta-blockers and glucose control. *Drug Intell Clin Pharm.* 1985; 19: 246-251. Web site. <http://euro-pepmc.org/abstract/med/2861072>. Accessed July 26, 2016
41. Connelly KA, Yan AT, Leiter LA, Bhatt DL, Verma S. Cardiovascular implications of hypoglycemia in diabetes mellitus. *Circulation.* 2015; 132(24): 2345-2350. doi: [10.1161/CIRCULATIONAHA.115.015946](https://doi.org/10.1161/CIRCULATIONAHA.115.015946)
42. Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: A systematic review and meta-analysis of population based studies. *PLoS One.* 2015; 10(6): e0126427. doi: [10.1371/journal.pone.0126427](https://doi.org/10.1371/journal.pone.0126427)